• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
RNA (miRNA, RNAi & siRNA) Therapy in Oncology Drug Pipeline Update 2014 Product Image

RNA (miRNA, RNAi & siRNA) Therapy in Oncology Drug Pipeline Update 2014

  • Published: March 2014
  • Region: Global
  • Bioseeker

Potentially any disease-causing gene, cell type or tissue can be targeted with miRNA, RNAi or siRNA, including those not ’druggable’ with small molecules or protein-based therapies.
There are today 56 companies plus partners developing 96 RNA (miRNA, RNAi & siRNA) drugs in 129 developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount to another 25 drugs. Rna (Mirna, Rnai & Sirna) Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 63 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 42 out of the 42 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 24 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

How May Drug Pipeline READ MORE >



Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos